Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis
{{output}}
Background and aims: The incidences and specific risk factors for cardiovascular adverse events (CVAEs) during osimertinib treatment remain uncertain. Methods: ... ...
